NOTE

🌱 created from: peripheral T cell lymphoma

propel

• (Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma)

• 30 mg/m2/wk for 6 weeks in 7-week cycles.

• The response rate in 109 evaluable patients was

  • 29% (32 of 109),
    • including 12 complete responses (11%) and
    • 20 partial responses (18%), with a median DoR of 10.1 months.

• Median PFS and OS were

  • 3.5 And 14.5 Months, Respectively.

• The Most Common Grade 3/4 Adverse Events Were Thrombocytopenia (32%), Mucositis (22%), Neutropenia (22%), And Anemia (18%).

O’Connor OA. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. Journal of Clinical Oncology. Published online March 20, 2011.